

Is Ivermectin a Cancer Solution?

By [Dr. Joseph Mercola](#)

Global Research, May 13, 2022

[Mercola](#)

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on [Instagram](#), [Twitter](#) and [Facebook](#). Feel free to repost and share widely Global Research articles.

Ivermectin has notable antitumor effects, which include inhibiting proliferation, metastasis and angiogenic activity in cancer cells

Ivermectin may target cancer in multiple ways, including inducing apoptosis and autophagy while also inhibiting tumor stem cells and reversing multidrug resistance

Along with direct cytotoxic effects, it’s believed that ivermectin regulates the tumor microenvironment, mediating immunogenic cell death

The development of an injectable form of ivermectin, or liposomal ivermectin, could help overcome some of its limitations regarding solubility, and open its use to a broader range of cancers

Considering that the “war against cancer” has been ongoing for decades, with little to show in terms of lives saved, repurposing existing drugs with favorable safety profiles and notable anticancer effects — like ivermectin — makes sense

*

Ivermectin is a widely used antiparasitic drug that’s listed on the World Health Organization’s essential medicines list¹ and approved by the U.S. Food and Drug Administration. In low- and middle-income countries, ivermectin is commonly used to treat parasitic diseases including onchocerciasis (river blindness), strongyloidiasis and other diseases caused by soil-transmitted helminthiasis, or parasitic worms.²


The drug is also used to treat scabies and lice. It’s estimated that the total number of ivermectin doses distributed is equal to one-third of the world’s population and, as such, “ivermectin at the usual doses (0.2–0.4 mg/kg) is considered extremely safe for use in humans.”³

Ivermectin also has demonstrated antiviral and anti-inflammatory properties and made headlines for its potential role in treating COVID-19⁴ — although much of the positive press has been censored and falsely labeled misinformation.⁵ Now researchers are highlighting another potential use for ivermectin, which is equally as exciting as its potential role in COVID-19 — as an anticancer agent.

Ivermectin's Powerful Antitumor Effects

Ivermectin has notable antitumor effects, which include inhibiting proliferation, metastasis and angiogenic activity in cancer cells.⁶ It appears to inhibit tumor cells by regulating multiple signaling pathways, which researchers explained in the *Pharmacological Research* journal, “suggests that ivermectin may be an anticancer drug with great potential.”⁷

Their graphic, below, shows the multiple ways that ivermectin may target cancer, including inducing apoptosis and autophagy while also inhibiting tumor stem cells and reversing multidrug resistance. They stated that ivermectin “exerts the optimal effect when used in combination with other chemotherapy drugs.”⁸



[Pharmacol Res. 2021 Jan; 163: 105207](#)

Many may not be aware that scientists Satoshi ōmura and William C. Campbell won the Nobel Prize in Physiology or Medicine in 2015 for their discovery of ivermectin.⁹ The medicine is used to treat not only parasitic diseases like malaria but also shows promise for treating asthma and neurological diseases, in addition to cancer.

Along with direct cytotoxic effects, it's believed that ivermectin regulates the tumor microenvironment, mediating immunogenic cell death — another reason for its promise as an anticancer agent.¹⁰ Research suggests the drug may be useful for the following cancers:¹¹

Breast cancer — The proliferation of multiple breast cancer cell lines was significantly reduced following treatment with ivermectin.
Digestive system cancer — Ivermectin significantly inhibited the proliferation of gastric cancer cells in vivo and in vitro. The drug also inhibited colorectal cancer cell lines and inhibited the development of hepatocellular carcinoma (liver cancer).
Urinary system cancer — Ivermectin significantly inhibited the proliferation of five renal (kidney) cell carcinoma lines without affecting normal kidney cells. It also had an inhibitory effect on prostate cancer cells.
Hematological cancer — In one study, ivermectin killed leukemia cells at low concentrations while leaving normal hematopoietic cells unharmed.
Reproductive system cancer — Ivermectin inhibited the proliferation of ovarian cancer cell lines and enhanced the efficacy of the conventional chemotherapy drug cisplatin, improving the treatment of epithelial ovarian cancer.
Brain glioma — Ivermectin inhibited the proliferation of human glioblastoma cells in a dose-dependent manner.
Respiratory system cancer — Ivermectin inhibited the development of nasopharyngeal carcinoma in mice, using doses that were not toxic to immune cells known as thymocytes. Ivermectin also significantly inhibited the proliferation of lung cancer cells and may reduce the metastasis of lung cancer cells.
Melanoma — When melanoma cells were treated with ivermectin, their activity was effectively inhibited.

Ivermectin Shows Promise Against Colorectal Cancer

A study published in *Frontiers in Pharmacology* specifically highlighted ivermectin's potential to fight colorectal cancer, which is the third most common cancer worldwide.¹² The drug was found to inhibit colorectal cancer cell growth in a dose-dependent manner as well as promote cell apoptosis.

Further, even at low doses of 2.5 and 5 μ M, ivermectin induced cell arrest in colorectal cancer, leading researchers to state, “[I]vermectin might be a new potential anticancer drug therapy for human colorectal cancer and other cancers.”¹³ Considering that the “war against cancer” has been ongoing for decades, with little to show in terms of lives saved, repurposing existing drugs with favorable safety profiles and notable anticancer effects — like ivermectin — makes sense.

The Pharmacological Research scientists similarly noted, “Drug repositioning is a shortcut to accelerate the development of anticancer drugs.”¹⁴ Not only has ivermectin been shown to permeate tumor tissues effectively, but it has a long history of successful use in humans.

They explained that even when doses were increased, no serious adverse effects were found:¹⁵

“[T]he broad-spectrum antiparasitic drug IVM (ivermectin), which is widely used in the field of parasitic control, has many advantages that suggest that it is worth developing as a potential new anticancer drug. IVM selectively inhibits the proliferation of tumors at a dose that is not toxic to normal cells and can reverse the MDR [multidrug resistance] of tumors.

Importantly, IVM is an established drug used for the treatment of parasitic diseases such as river blindness and elephantiasis. It has been widely used in humans for many years, and its various pharmacological properties, including long- and short-term toxicological effects and drug metabolism characteristics are very clear. In healthy volunteers, the dose was increased to 2 mg/Kg, and no serious adverse reactions were found ...”

Is Liposomal Delivery a Game Changer?

The development of an injectable form of ivermectin, or liposomal ivermectin, could help overcome some of its limitations regarding solubility and open its use to a broader range of cancers. The cancer immunotherapy treatment pembrolizumab, for instance, is approved to treat PD-L1-positive, triple-negative breast cancer, which accounts for only about 20% of cases.

As an immune checkpoint inhibitor, it works best in so-called “hot” tumors, which are already infiltrated by T cells. If ivermectin could be injected into the tumor, inducing T-cell infiltration into the area and inducing immunogenic cancer cell death, it’s possible that it could turn a “cold” tumor into a “hot” one, thereby making it more effectively treated.¹⁶

Biotech company Mountain Valley MD has developed a liposomal delivery system for ivermectin that they believe could dramatically widen its treatment potential. In an interview with Medical Update Online, Dennis Hancock, Mountain Valley MD president and CEO, explained:¹⁷

“So the business value proposition really simply is, we take the best-selling and best-acting drugs and expand their ability to be used on ... more types of cancer on a broader spectrum. So you still need the cancer drug and what our Ivectosol does is it enables it to be used in a broader universe ...

What’s really exciting about the work that Mountain Valley MD is doing is we’re enabling drugs that have already been proven in their efficacy and safety to do better and do more faster — so we’re not asking people to ‘wait five years and see’...”

Most of the research involving ivermectin for cancer to date involves oral or in-vitro administration. Mountain Valley MD is conducting preclinical trials using liposomal ivermectin for metastatic melanoma, non-small cell lung cancer, triple-negative breast cancer and possibly bladder cancers. They also have plans to produce liposomal ivermectin for use in human trials.¹⁸ In a news release, Mike Farber, director of life sciences at Mountain Valley MD, stated:¹⁹

“The extensive research supporting the drug ivermectin as effective in the inhibition of proliferation, metastasis, and angiogenic activity in a variety of cancers, and as an initiator of immunogenic cell death, is overwhelming. Imagine what is possible when you have the world’s only human injectable form of ivermectin that can be directly injected into a tumor or provided through more bio-available forms such as intravenously.

We believe this will be groundbreaking research with near-immediate application to be able to proceed directly to human trials based on the safety and efficacy of ivermectin.”

What About Ivermectin for SARS-CoV-2?

In the U.S., ivermectin has been vilified as a treatment for SARS-CoV-2, despite its impressive inhibitory effects on the virus.²⁰ Even the FDA has a dedicated webpage warning “why you should not use ivermectin to prevent COVID-19.”²¹

It’s interesting to note, however, that Africa has a lower number of cases, severity of disease, hospitalizations and deaths than other areas of the world,²² which may be due to using prophylactic medications for endemic infections — ivermectin and others, such as sweet wormwood — that have successfully treated COVID-19.

For instance, a study from Japan demonstrated that just 12 days after doctors were allowed to legally prescribe ivermectin to their COVID-19 patients, the cases dropped dramatically.²³

The chairman of the Tokyo Medical Association²⁴ noticed the low number of infections and deaths in Africa, where many use ivermectin prophylactically and as the core strategy to treat river blindness.²⁵ More than 99% of people infected with river blindness live in 31 African countries.

Aside from these observations, a study published in the March 2022 issue of the International Journal of Infectious Diseases found that treatment with ivermectin reduced mortality in COVID-19 patients — and to a greater degree than remdesivir.²⁶

Another recent investigation by Cornell University, posted on the University’s preprint server January 20, 2022, found ivermectin outperformed 10 other drugs against COVID-19, making it the most effective against the Omicron variant.²⁷ It even outperformed nirmatrelvir (Paxlovid), which was granted emergency use authorization against COVID-19 in December 2021.

Remdesivir costs between \$2,340 and \$3,120,²⁸ and nirmatrelvir costs \$529 per treatment,²⁹ while ivermectin’s average treatment cost is \$58.³⁰ Do you think this has anything to do with ivermectin’s vilification?

Dr. Pierre Kory, who is part of the group that formed the Front Line COVID-19 Critical Care Working Group (FLCCC) to advance early treatments for COVID-19, pleaded with the U.S. government early on in the pandemic to review the expansive data on ivermectin to prevent COVID-19, and to keep those with early symptoms from progressing and help critically ill patients recover — to no avail.^{31,32}

However, if you'd like to learn more about its potential uses for SARS-CoV-2, FLCCC's I-MASK+ protocol can be downloaded in full,³³ giving you step-by-step instructions on how to prevent and treat the early symptoms of COVID-19.

FLCCC also has protocols for at-home prevention and early treatment, called I-MASS, which involves ivermectin, vitamin D3, a multivitamin and a digital thermometer to watch your body temperature in the prevention phase and ivermectin, melatonin, aspirin and antiseptic mouthwash for early at-home treatment.

Household or close contacts of COVID-19 patients may take ivermectin (18 milligrams, then repeat the dose in 48 hours) for post-exposure prevention.³⁴ Whether ivermectin's potential as an anticancer agent will be stifled the same way it was for COVID-19 remains to be seen, but it appears to be a compound that's worth watching as a potential powerful agent in the fight against cancer.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

Notes

^{1, 2} [WHO March 31, 2021](#)

³ [American Journal of Therapeutics: July/August 2021 – Volume 28 – Issue 4 – p e434-e460](#)

⁴ [In Vivo. Sep-Oct 2020;34\(5\):3023-3026. doi: 10.21873/invivo.12134](#)

⁵ [Trial Site News November 27, 2021, 3:52](#)

^{6, 7, 8} [Pharmacol Res. 2021 Jan; 163: 105207](#)

^{9, 20} [Pharmacol Res. 2021 Jan; 163: 105207., Introduction](#)

¹⁰ [Pharmacol Res. 2021 Jan; 163: 105207., 2.1 Breast cancer](#)

¹¹ [Pharmacol Res. 2021 Jan; 163: 105207., 2. The role of IVM in different cancers](#)

^{12, 13} [Front Pharmacol. 2021; 12: 717529](#)

^{14, 15} [Pharmacol Res. 2021 Jan; 163: 105207., Summary](#)

^{16, 17, 18} [Medical Update Online June 19, 2021](#)

¹⁹ [Mountain Valley MD May 3, 2021](#)

²¹ [U.S. Food and Drug Administration, Why You Should Not Use Ivermetin to Prevent COVID-19](#)

- ²² [AP News, November 19, 2021](#)
- ²³ [YouTube, November 23, 2021 Min 1:25](#)
- ²⁴ [Tokyo Web, August 13, 2021](#)
- ²⁵ [World Health Organization, Onchocerciasis](#)
- ²⁶ [International Journal of Infectious Diseases March 2022; 116\(Supplement\): S40](#)
- ²⁷ [Cornell University, January 20, 2022](#)
- ²⁸ [AJMC June 29, 2020](#)
- ²⁹ [Precision Vaccinations, November 19, 2021](#)
- ³⁰ [JAMA 2022;327\(6\):584-587](#)
- ³¹ [FLCCC Alliance, Ivermectin & COVID-19](#)
- ³² [Mountain Home May 1, 2021](#)
- ³³ [FLCCC Alliance, I-Mask+](#)
- ³⁴ [FLCCC Alliance, I-MASS](#)

The original source of this article is [Mercola](#)
Copyright © [Dr. Joseph Mercola](#), [Mercola](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Joseph Mercola](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted

material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca